An economic evaluation of dasatinib as a treatment for chronic phase chronic myeloid leukaemia in Scotland

被引：1
|
作者：
Taylor, M. J. [1 ]
Minda, K. [2 ]
Cerri, K. H. [3 ]
Davis, C. [4 ]
Kan, H. J. [4 ]
Ray, S. [2 ]
机构：
[1] Univ York, York YO10 5DD, N Yorkshire, England
[2] Bristol Myers Squibb Pharmaceut, Uxbridge, Middx, England
[3] Bristol Myers Squibb Co, New York, NY 10154 USA
[4] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)64889-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A233 / A233
页数：1
相关论文
共 50 条
  • [41] Responses to Dasatinib as a Second- and Third-Line Tyrosine Kinase Inhibitor in Chronic Phase Chronic Myeloid Leukaemia Patients
    Tan, Jiaqi
    Xue, Mengxing
    Pan, Jinlan
    Cen, Jiannong
    Qi, Xiaomei
    Liu, Ping
    Zhao, Xiaohong
    Wu, Pin
    Wang, Qinrong
    Liu, Dandan
    Liu, Yuejun
    Chen, Suning
    Wang, Zhi
    ACTA HAEMATOLOGICA, 2019, 142 (02) : 79 - 86
  • [42] Dasatinib A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
    McCormack, Paul L.
    Keam, Susan J.
    DRUGS, 2011, 71 (13) : 1771 - 1795
  • [43] Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase
    Roux, Clemence
    Nicolini, Franck-Emmanuel
    Rea, Delphine
    Niault, Mathilde
    Mollica, Luigina
    Berger, Francoise
    Chassagne-Clement, Catherine
    Tigaud, Isabelle
    Tulliez, Michel
    Giraudier, Stephane
    Turhan, Ali
    Rousselot, Philippe
    Legros, Laurence
    BLOOD, 2013, 122 (17) : 3082 - 3083
  • [44] Economic Evaluation of Dasatinib in the Treatment of Chronic Myeloid Leukemia Patients Resistant to Imatinib in Chile (vol 11, 2011)
    不详
    MEDWAVE, 2011, 11 (04):
  • [45] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [46] Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity
    Copland, Mhairi
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (05) : 665 - 678
  • [47] Leukaemia cutis as the initial manifestation in a child with brachydactyly in chronic phase of chronic myeloid leukaemia
    Wang, Shuye
    Xu, Haobo
    Liu, Yabo
    He, Wanting
    Wang, Wei
    PATHOLOGY, 2014, 46 (06) : 569 - 570
  • [48] Is there really an accelerated phase of chronic myeloid leukaemia?
    Gale, Robert Peter
    Jiang, Qian
    Apperley, Jane F.
    Hochhaus, Andreas
    LEUKEMIA, 2024, 38 (10) : 2085 - 2086
  • [49] Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
    Ishida, Yoji
    Murai, Kazunori
    Yamaguchi, Kohei
    Miyagishima, Takuto
    Shindo, Motohiro
    Ogawa, Kazuei
    Nagashima, Takahiro
    Sato, Shinji
    Watanabe, Reiko
    Yamamoto, Satoshi
    Hirose, Takayuki
    Saitou, Souich
    Yonezumi, Masakatsu
    Kondo, Takeshi
    Kato, Yuichi
    Mochizuki, Noboru
    Ohno, Keiko
    Kishino, Satoshi
    Kubo, Kohmei
    Oyake, Tatsuo
    Ito, Shigeki
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 185 - 193
  • [50] Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses
    Pavey, T.
    Hoyle, M.
    Ciani, O.
    Crathorne, L.
    Jones-Hughes, T.
    Cooper, C.
    Osipenko, L.
    Venkatachalam, M.
    Rudin, C.
    Ukoumunne, O.
    Garside, R.
    Anderson, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2012, 16 (42) : 1 - +
12345